GLP-1 Receptor Agonist Market b y Drug Class, by Route of Administration, by Application, by Distribution, Global Forecast, 20242032 (GMI, 2023)
Patients should be monitored for treatment response through serial measurements of weight, waist circumference, glycemic parameters, and lipid profiles
Secondary endpoints in the trial emulations as well as in their respective reference trials were not powered sufficiently to assess statistical agreement
Diabetes can also put you at a higher risk for hair loss if you experience rapid, significant weight loss
Diabetes and the risk of stroke
Lifestyle changes remain the foundation of weight loss, and FDA-approved GLP-1 medications may be an option when recommended and prescribed by a qualified healthcare provider